MedTrace Logo

TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC

NCT04992143 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-02-16

No results posted yet for this study

Summary

According to the BCLC staging system treatment recommendation, systemic treatment is recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for patients in this stage. Studies have shown that TACE combined with sorafenib therapy has shown effectiveness in the treatment of advanced liver cancer, and PD-1 inhibitors have also shown effectiveness in the treatment of advanced liver cancer. Therefore, in order to improve the survival benefit of BCLC stage C liver cancer patients, this clinical study was designed to evaluate the effectiveness and safety of TACE combined with sorafenib and tislelizumab in the treatment of BCLC stage C liver cancer patients.

Conditions

  • BCLC Stage C Hepatocellular Carcinoma

Interventions

PROCEDURE

TACE

TACE first ,and more TACE could be performed when it is necessary.

DRUG

Tilelizumab

Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE

DRUG

Sorafenib

Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Principal Investigators

  • Jun-hui Sun, MD,PH.D · First Affiliated Hospital of Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-20
Primary Completion
2023-08-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04992143 on ClinicalTrials.gov